Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comment on the JAVELIN study: RCC immunotherapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.10.18
Views: 490

Prof John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Prof Jon Haanan comments at ESMO 2018 on the JAVELIN Renal 101 study for the use of avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma.

For more on these findings, watch Dr Motzer present the trial findings at the conference.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation